MedPath

Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study

Not Applicable
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Device: communication system P300 Speller
Registration Number
NCT01897818
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Brief Summary

ALS is a severe progressive neurodegenerative disease characterized by degeneration motor neurons leading to death in 3 to 5 years. Gradually in time, the patient deprived of all motor skills as well as the possibility of communication written and oral developing a state close Locked In Syndrome (LIS). The main objective is to establish the feasibility of brain-computer interface using the pathological condition, with dependent disabled subjects as a means of communication.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • age >= 18
  • have a diagnosis of ALS suspected, possible, probable with EMG
  • be able to follow the study process and to comply with the schedule of visits upon entry into the study
  • understand the purpose of the study
  • expressing P300 wave in the conditions of the study
Exclusion Criteria
  • have a mental illness or clinical dementia defined clinically significant may hinder the patient's ability to follow the procedures of the study
  • have a significant history of photosensitive epilepsy
  • have a history of allergy to the gel used for the electrodes
  • Major protected by law (guardianship, curators)
  • have uncorrectable visual disorders
  • not being able to maintain a sitting position and focus on a computer screen for more than 30 min.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ALS patientscommunication system P300 Speller-
Primary Outcome Measures
NameTimeMethod
the full achievement of "copy spelling" and "free spelling" tests session 114 days after inclusion
the full achievement of "copy spelling" and "free spelling" tests session 228 days after inclusion
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hôpital de l'Archet I

🇫🇷

Nice, France

© Copyright 2025. All Rights Reserved by MedPath